Stephen P. Creekmore
Publications by Year
Research Areas
Immune Cell Function and Interaction, CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, T-cell and B-cell Immunology
Most-Cited Works
- → Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer(2014)691 cited
- → Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma(1999)591 cited
- → A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.(1989)236 cited
- Alterations in T cell receptor and signal transduction molecules in melanoma patients.(1995)
- → Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques(2011)191 cited
- → IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion(2019)132 cited
- → Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates(2010)121 cited
- → IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood(2011)99 cited
- → In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.(1988)79 cited
- → Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia(2012)70 cited